10x Genomics, Inc. (TXG)
| Previous close | 21.54 |
| Open | 21.54 |
| Bid | 22.03 x 400 |
| Ask | 22.18 x 400 |
| Day's range | 21.45 - 22.36 |
| 52-week range | 15.28 - 57.90 |
| Volume | |
| Avg. volume | 1,836,764 |
| Market cap | 2.665B |
| Beta (5Y monthly) | 1.85 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -2.03 |
| Earnings date | 31 Oct 2024 - 04 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 27.43 |
PR Newswire10x Genomics Unveils Chromium Xo: A Low-Cost Instrument to Expand Access to High-Performance Single Cell Research
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of Chromium Xo, a new addition to its fleet of Chromium single cell instruments. Designed to meet the needs of researchers who desire high-quality data on limited budgets, Chromium Xo offers an affordable entry point into routine, high-performance single cell analysis.
- PR Newswire
10x Genomics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, at 10:45 a.m. Eastern Time.
GuruFocus.comCatherine Wood's Strategic Acquisition in 10x Genomics Inc.
On July 31, 2024, Catherine Wood (Trades, Portfolio)'s firm made a significant addition to its investment portfolio by acquiring 2,043,248 shares of 10x Genomics Inc. (NASDAQ:TXG). The shares were purchased at a price of $20.67, reflecting a strategic move to capitalize on the current market valuation of TXG. Catherine Wood (Trades, Portfolio), with over four decades of experience in investment management, founded ARK in 2014 with a focus on disruptive innovation.
